![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF28 |
Gene summary for ZNF28 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF28 | Gene ID | 7576 |
Gene name | zinc finger protein 28 | |
Gene Alias | KOX24 | |
Cytomap | 19q13.41 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P17035 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7576 | ZNF28 | HCC1_Meng | Human | Liver | HCC | 2.43e-48 | 6.36e-02 | 0.0246 |
7576 | ZNF28 | HCC1 | Human | Liver | HCC | 1.50e-02 | 2.64e+00 | 0.5336 |
7576 | ZNF28 | HCC2 | Human | Liver | HCC | 3.70e-08 | 2.41e+00 | 0.5341 |
7576 | ZNF28 | S015 | Human | Liver | HCC | 5.56e-06 | 2.53e-01 | 0.2375 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00488638 | Esophagus | ESCC | stem cell differentiation | 122/8552 | 206/18723 | 5.95e-05 | 4.59e-04 | 122 |
GO:00101711 | Esophagus | ESCC | body morphogenesis | 30/8552 | 43/18723 | 1.21e-03 | 5.88e-03 | 30 |
GO:004886311 | Liver | Cirrhotic | stem cell differentiation | 66/4634 | 206/18723 | 1.06e-02 | 4.68e-02 | 66 |
GO:00488637 | Oral cavity | OSCC | stem cell differentiation | 96/7305 | 206/18723 | 1.55e-02 | 4.99e-02 | 96 |
GO:00101713 | Thyroid | PTC | body morphogenesis | 23/5968 | 43/18723 | 2.66e-03 | 1.35e-02 | 23 |
GO:004886318 | Thyroid | PTC | stem cell differentiation | 85/5968 | 206/18723 | 2.71e-03 | 1.36e-02 | 85 |
GO:001017111 | Thyroid | ATC | body morphogenesis | 28/6293 | 43/18723 | 2.35e-05 | 2.06e-04 | 28 |
GO:004886321 | Thyroid | ATC | stem cell differentiation | 97/6293 | 206/18723 | 3.88e-05 | 3.15e-04 | 97 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF28 | SNV | Missense_Mutation | c.951T>A | p.His317Gln | p.H317Q | P17035 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-BC-4073-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Targeted Molecular therapy | sorafenib | SD | |
ZNF28 | SNV | Missense_Mutation | rs369691107 | c.1550A>G | p.His517Arg | p.H517R | P17035 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-CC-A7IH-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
ZNF28 | SNV | Missense_Mutation | c.2116N>G | p.Leu706Val | p.L706V | P17035 | protein_coding | deleterious(0) | benign(0.304) | TCGA-CC-A7II-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
ZNF28 | SNV | Missense_Mutation | novel | c.1540N>G | p.Gln514Glu | p.Q514E | P17035 | protein_coding | tolerated(0.06) | benign(0.02) | TCGA-CC-A8HS-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
ZNF28 | SNV | Missense_Mutation | novel | c.76G>A | p.Asp26Asn | p.D26N | P17035 | protein_coding | tolerated(0.11) | probably_damaging(0.994) | TCGA-05-4424-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | erlotinib | SD |
ZNF28 | SNV | Missense_Mutation | novel | c.1397C>A | p.Pro466Gln | p.P466Q | P17035 | protein_coding | deleterious(0) | possibly_damaging(0.855) | TCGA-55-6983-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | chemo | CR |
ZNF28 | SNV | Missense_Mutation | c.465G>T | p.Gln155His | p.Q155H | P17035 | protein_coding | tolerated(0.13) | benign(0.01) | TCGA-75-6206-01 | Lung | lung adenocarcinoma | Male | Unknown | I/II | Unknown | Unknown | SD | |
ZNF28 | SNV | Missense_Mutation | c.371N>A | p.Gly124Asp | p.G124D | P17035 | protein_coding | tolerated(1) | benign(0) | TCGA-91-6831-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ZNF28 | SNV | Missense_Mutation | c.160N>G | p.Met54Val | p.M54V | P17035 | protein_coding | tolerated(1) | benign(0) | TCGA-97-7554-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | alimta | SD | |
ZNF28 | SNV | Missense_Mutation | novel | c.1164N>G | p.Cys388Trp | p.C388W | P17035 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-21-1081-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |